1. Home
  2. ENTA vs NUS Comparison

ENTA vs NUS Comparison

Compare ENTA & NUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$14.06

Market Cap

374.6M

Sector

Health Care

ML Signal

HOLD

Logo Nu Skin Enterprises Inc.

NUS

Nu Skin Enterprises Inc.

HOLD

Current Price

$7.65

Market Cap

343.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
NUS
Founded
1995
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Other Pharmaceuticals
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
374.6M
343.1M
IPO Year
2012
1996

Fundamental Metrics

Financial Performance
Metric
ENTA
NUS
Price
$14.06
$7.65
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$20.40
N/A
AVG Volume (30 Days)
110.5K
392.0K
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
3.08%
EPS Growth
29.93
207.80
EPS
N/A
3.18
Revenue
$102,814,000.00
$3,176,718,000.00
Revenue This Year
$7.76
N/A
Revenue Next Year
N/A
$7.14
P/E Ratio
N/A
$2.45
Revenue Growth
16.48
48.98
52 Week Low
$4.96
$5.32
52 Week High
$17.15
$14.62

Technical Indicators

Market Signals
Indicator
ENTA
NUS
Relative Strength Index (RSI) 57.22 51.05
Support Level $13.39 $7.03
Resistance Level $15.52 $10.90
Average True Range (ATR) 0.76 0.22
MACD 0.20 0.11
Stochastic Oscillator 74.84 71.86

Price Performance

Historical Comparison
ENTA
NUS

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About NUS Nu Skin Enterprises Inc.

Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.

Share on Social Networks: